There are 2934 resources available
State of the art management of medullary thyroid cancer
Presenter: Furio Pacini
Session: Recent advances in thyroid cancer
Resources:
Slides
Webcast
Tumour growth rate as a driver to commence treatment with TKI in RA-refractory differentiated thyroid carcinoma
Presenter: Sebastiano Filetti
Session: Recent advances in thyroid cancer
Resources:
Slides
Webcast
The role of Artificial Intelligence (AI)
Presenter: Nikos Paragios
Session: Where will future technologies take us in metastatic breast cancer?
Resources:
Slides
Webcast
Rationale for, and an orientation to, immunotherapy
Presenter: Lana Kandalaft
Session: Update on novel therapies in ovarian cancer
Resources:
Slides
Webcast
Results of immunotherapy trials in ovarian cancer: Where do we stand in 2019?
Presenter: Antonio González Martín
Session: Update on novel therapies in ovarian cancer
Resources:
Slides
Webcast
Where do we stand with PARP inhibitors in ovarian cancer treatment in 2019?
Presenter: Jonathan Ledermann
Session: Update on novel therapies in ovarian cancer
Resources:
Slides
Webcast
Do we already have biomarkers that may predict response and/or resistance to PARP inhibitors?
Presenter: Charlie Gourley
Session: Update on novel therapies in ovarian cancer
Resources:
Slides
Webcast
Does radiotherapy still have a role in stage III NSCLC in the era of immunotherapy? The radiotherapist’s view
Presenter: Kevin Franks
Session: Immunotherapy in thoracic malignancies: What has been achieved in 2019?
Resources:
Slides
Webcast
Where is immunotherapy for small cell lung cancer and mesothelioma now?
Presenter: Alessandra Curioni
Session: Immunotherapy in thoracic malignancies: What has been achieved in 2019?
Resources:
Slides
Webcast
905PD - Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC)
Presenter: Andrea Necchi
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides